OM1 is a Boston, MA–based health technology company focused on real-world outcomes for chronic conditions. Led by CEO and founder Dr. Richard Gliklich, OM1 partners with providers, medical societies, payers, and manufacturers to harness real-world data for medical research, evaluating health outcomes, regulatory approvals, and personalizing treatment. The company builds and maintains a real-world data cloud, clinical registries, and an AI platform to generate real-world evidence and support personalized medicine across specialties including dermatology, rheumatology, cardiology, gastroenterology, respiratory, neurosciences, and behavioral health. OM1 also develops AI models and solutions for patient-finding and outcome prediction. The company plans to use the $85M to expand its real-world data cloud, clinical registries, and AI platform for real-world evidence and personalized medicine. OM1 was founded in 2015 by the leadership team of Outcome Sciences, the pioneering real-world research company acquired in 2011. OM1 is a real-world outcomes and technology company that organizes health information and applies AI to generate real-world evidence. It offers a real-world data cloud, clinical registries, and AI solutions that enable regulators, payers, and providers to generate and use RWE more rapidly and effectively. The company focuses on therapeutic areas including immunology, rheumatology, cardiometabolic disorders, musculoskeletal conditions and CNS/behavioral health. Among its products are therapeutic-focused registries for rheumatoid arthritis and systemic lupus erythematosus and AI tools for measuring and predicting outcomes for patients and populations. OM1 intends to use the new funding to expand its real-world data cloud and clinical registries to support personalized medicine and real-world evidence generation. The company is led by founder and CEO Dr. Richard Gliklich and is based in Boston, MA. OM1, founded in 2015 by Dr. Richard Gliklich and based in Boston, MA, builds intelligent, data-driven health outcomes solutions. The company uses standardized health information and artificial intelligence to gather, synthesize and leverage large clinical datasets and registries. Its platform enables customers to understand, compare and predict health outcomes to personalize patient care. OM1 plans to use the new funding to continue the buildout of its intelligent, data-driven solutions. The company has attracted venture investors and is expanding its technical and product capabilities to support outcome measurement and prediction. OM1 provides an analytics platform that gathers, synthesizes and enriches clinical data to produce measurements and AI-driven insights and predictions about real-world healthcare outcomes. The system is designed to improve clinical, financial and operational management for healthcare stakeholders by offering a more holistic view of outcomes. Its analytics aim to help healthcare organizations optimize care for individuals and populations, inform smart supply chain decisions, and link outcomes to value. Led by founder and CEO Rich Gliklich, the company emphasizes AI and big-data techniques in its product. OM1 intends to use the Series A proceeds to continue the buildout of its technology platform.

Total raised

$171M

Funding rounds

4

Latest round

Series D

Latest activity

Jul 2021